Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukemia-associated antigens in ALL.

J M Pesando, J Ritz, H Lazarus

    Blood
    |December 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.

    Leukemia·2017
    Same author

    Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.

    Bone marrow transplantation·2017
    Same author

    Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge?

    Bone marrow transplantation·2017
    Same author

    Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation.

    Bone marrow transplantation·2016
    Same author

    Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant.

    Bone marrow transplantation·2016
    Same author

    Arrhythmias in the setting of hematopoietic cell transplants.

    Bone marrow transplantation·2015
    Same journal

    Decentralized Clinical Trials in Hematology: the Promise and the Peril.

    Blood·2026
    Same journal

    How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

    Blood·2026
    Same journal

    The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

    Blood·2026
    Same journal

    Precision Transfusion Medicine in the Omics Era.

    Blood·2026
    Same journal

    Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

    Blood·2026
    Same journal

    Identifying steroid-refractory aGVHD before it happens.

    Blood·2026
    See all related articles

    A new antiserum, common acute lymphoblastic leukemia antigen (CALLA), effectively identifies most non-T-cell acute lymphoblastic leukemia (ALL) cells. This discovery aids in distinguishing ALL from other hematologic malignancies.

    Area of Science:

    • Immunology
    • Hematology
    • Oncology

    Background:

    • Acute lymphoblastic leukemia (ALL) is a heterogeneous disease.
    • Accurate diagnosis and classification are crucial for effective treatment.
    • Distinguishing ALL from other hematologic malignancies, such as acute myelogenous leukemia (AML), can be challenging.

    Purpose of the Study:

    • To develop and characterize a specific antiserum for non-T-cell ALL.
    • To evaluate the diagnostic utility of this antiserum in differentiating various leukemic subtypes.
    • To assess the correlation of antiserum reactivity with established diagnostic markers and patient demographics.

    Main Methods:

    • Preparation of a cytotoxic antiserum (CALLA) using leukemic cell lines for absorption.
    • Testing CALLA reactivity against a panel of leukemia cell lines and primary patient samples, including non-T-cell ALL, T-cell ALL, AML, chronic myelogenous leukemia in blast crisis, and other hematologic malignancies.

    Related Experiment Videos

  • Comparison of CALLA reactivity with periodic acid Schiff (PAS) staining and analysis of reactivity across different age groups.

    • Main Results:

    • CALLA specifically reacted with leukemic cells from 82% of non-T-cell ALL patients.
    • Minimal reactivity was observed in AML (1%), chronic myelogenous leukemia in blast crisis (29%), and other hematologic malignancies (8%).
    • CALLA did not react with normal hematopoietic cells or T-cell ALL lines, demonstrating high specificity.

    Conclusions:

    • The developed CALLA antiserum is a valuable tool for identifying non-T-cell ALL.
    • Combined with antisera for Ia-like and T-cell antigens, CALLA significantly improves the ability to distinguish ALL from AML and other hematologic malignancies.
    • CALLA reactivity shows some age-related patterns and poor correlation with PAS staining, suggesting distinct biological characteristics.